MARKET

VRTX

VRTX

Vertex Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

176.00
-1.55
-0.87%
After Hours: 176.00 0 0.00% 17:07 09/17 EDT
OPEN
173.02
PREV CLOSE
177.55
HIGH
177.82
LOW
173.02
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
195.81
52 WEEK LOW
151.80
MARKET CAP
45.24B
P/E (TTM)
69.86
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VRTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VRTX News

  • The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial
  • Zacks.10h ago
  • Top Stock Reports for Celgene, Sinopec & HSBC
  • Zacks.1d ago
  • How Much Are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Insiders Taking Off The Table?
  • Simply Wall St..4d ago
  • Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
  • Zacks.4d ago

More

Industry

Biotechnology & Medical Research
+0.24%
Pharmaceuticals & Medical Research
+0.57%

Hot Stocks

Name
Price
%Change

About VRTX

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
More

Webull offers Vertex Pharmaceuticals Incorporated (VRTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.